Revenue halved to NZ$44.7m as Bremworth swings to a NZ$6.4m loss

The scale of that decline is the dominant event in this result. PBT swung from a NZ$18.6m profit in FY25 to a NZ$6.3m loss, and NPAT followed to a NZ$6.4m loss — though given the near-total reversal from a positive prior base, percentage growth rates are not analytically meaningful here. Management acknowledged the anticipated improvement in sales had not materialised, citing continued challenging trading conditions.

Operating cash flow turned negative at -NZ$1.9m, against NZ$15.7m in the prior comparable. Cash on hand fell to NZ$17.8m from NZ$42.2m. Capex of NZ$5.4m was dominated by Napier and Whanganui plant reinstatement costs, lifting capex intensity to 12.0% of revenue versus 6.2% in the prior period.

At 90.2 days, debtor days are 30.8 days above the company's historical mean of 59.4 days and above the prior three-year range of 47.9–81.9 days. On a revenue base that has halved, receivables of NZ$11.0m represent a disproportionately large balance-sheet claim. If collections do not accelerate as revenue recovers, the debtors position will continue to absorb cash.

Inventory days are at the upper edge of historical range. At 210.7 days — 52.9 days above the historical mean of 157.8 days — inventory is elevated relative to the current sales run-rate. Whether this reflects deliberate stocking for a recovery or sluggish clearance matters for future working-capital and margin trajectory.

The second-half recovery was dramatic but the full-year revenue base remains small. The HY26 interim showed NZ$42.1m of revenue and a NZ$8.1m loss. The implied second half contributed only NZ$2.6m of revenue and a NZ$1.7m profit, meaning essentially all second-half improvement came from cost discipline and working-capital release rather than top-line recovery. That is a fragile earnings quality signal.

The board's own expectation — that sales improvement would come through — was explicitly not met. The HY26 management letter noted investments in expanded NZ and Australian sales teams and plant reinstatement, suggesting FY27 is the more plausible recovery window rather than the current year.

The full-year revenue of NZ$44.7m annualises to the same figure; without a clear order pipeline or forward-work disclosure, it is not possible to assess whether the second-half sales base of approximately NZ$2.6m is a floor or a trough.

That release partially flatters operating cash flow relative to the underlying earnings loss. The interpretation hint from the company's historical baseline is clear: check reversibility before reading this as durable cash generation.

Capex of NZ$5.4m was predominantly plant reinstatement spending at Napier and Whanganui rather than growth investment, which is non-recurring in character but necessary for future capacity. The PBT-to-NPAT gap of NZ$0.1m and an effective tax rate of -1.4% (within the historical range of -21.2% to 6.1%) introduced no meaningful tax distortion to the read. ROE of -9.8% compares to a prior-year 25.2% and is below the company's historical range, reflecting the magnitude of the earnings swing.

This briefing cannot assess the forward sales pipeline, customer concentration risk, or whether the second-half profit of NZ$1.7m is repeatable without segment-level revenue disclosure and management guidance.